Key Highlights
Join others who leverage Pramana's unique solution with industry's highest quality imaging technology, enabling the fastest case turnaround times.
"Receiving Health Canada authorization is a major milestone in our commercialization strategy. It reflects the strength of our product development, quality, and regulatory readiness, and it opens the door to expanding access to our technology in a market known for strong clinical and academic institutions."
This regulatory milestone opens new opportunities to modernize their pathology workflows with AI-powered digital solutions.
Access to Pramana's clinical-grade scanners that can support hematopathology, cytopathology, anatomic pathology, and histopathology workflows simultaneously, radically improving return on investment.
Scalable deployment capabilities for both clinical and research environments, with AI-powered decision support that captures previously undetectable tissue features.
Prior to receiving Health Canada authorization, Pramana secured Medical Device Single Audit Program (MDSAP) certification, validating its quality management system and streamlining regulatory access across Canada, the United States, Brazil, Australia, and Japan. This builds on a strong pipeline of innovation with 23 issued and 54 pending patents across North America, Europe, and other international markets.